EUVIMEDEUVIMED entdecken
Multizentrische Studie

High‐risk screening for late‐onset Pompe disease in China: An expanded multicenter study

Kexin Jiao, Bochen Zhu, Xueli Chang, Junhong Guo, Jun Fu, Xueqin Song, Xuen Yu, Xiaoge Zhang, Jihong Dong, Wang Yan, Xinghua Luan, Zhiqiang Wang und 38 weitere

Journal of Inherited Metabolic Disease · 2025-01 · 48 (1)

DOI: 10.1002/jimd.12793 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 03.09.2024. Verfasst von Kexin Jiao und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, alpha-Glucosidases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Clinical Research Project Supported by Huashan Hospital, Fudan University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Late‐onset Pompe disease (LOPD) is caused by a genetic deficiency of the lysosomal enzyme acid alpha‐glucosidase (GAA), leading to progressive limb‐girdle weakness and respiratory impairment. The insidious onset of non‐specific early symptoms often prohibits timely diagnosis. This study aimed to validate the high‐risk screening criteria for LOPD in the Chinese population. A total of 726 patients were included, including 96 patients under 14 years of age. Dried blood spots (DBS) and tandem mass spectrometry (MS/MS) were employed to evaluate serum GAA activity. Forty‐four patients exhibited a decreased GAA activity, 16 (2.2%) of which were confirmed as LOPD by genetic testing. Three previously unreported GAA mutations were also identified. The median diagnostic delay was shortened to 3 years, which excelled the previous retrospective studies. At diagnosis, most patients exhibited impaired respiratory function and/or limb‐girdle weakness. Elevated serum creatine kinase (CK) levels were more frequently observed in patients who manifested before age 16. Overall, high‐risk screening is a feasible and efficient method to identify LOPD patients at an early stage. Patients over 1 year of age with either weakness in axial and/or proximal limb muscles, or unexplained respiratory distress shall be subject to GAA enzymatic test, while CK levels above 2 times the upper normal limit shall be an additional criterion for patients under 16. This modified high‐risk screening criteria for LOPD requires further validation in larger Chinese cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIalpha-GlucosidasesHumansMaleFemaleChinaAdolescentAdultChildYoung AdultChild, PreschoolMiddle AgedInfantMutationAge of OnsetDried Blood Spot TestingTandem Mass SpectrometryGenetic TestingRetrospective StudiesCreatine KinaseMass Screening

Stichwörter der Autor:innen

acid alpha‐glucosidasedried blood spotshigh‐risk screeninghyperCKemialate‐onset Pompe diseasemuscle weaknessrespiratory distresstandem mass spectrometry

Substanzen

alpha-GlucosidasesGAA protein, humanCreatine Kinase

Autor:innen und Institutionen

  • Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
  • National Center for Neurological Disorders (NCND), Huashan Rare Disease Center, Shanghai Medical College, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, China.
  • Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China.
  • Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Neurology, Institute of Neurology, Anhui University of Traditional Chinese Medicine, Hefei, China.

ORCID-Profile: Wenhua Zhu

Förderung

  • Clinical Research Project Supported by Huashan Hospital, Fudan University
  • National Natural Science Foundation of China

Zitieren

APA

Jiao, K., Zhu, B., Chang, X., Guo, J., Fu, J., Song, X., Yu, X., Zhang, X., Dong, J., Yan, W., Luan, X., Wang, Z., Han, H., Du, L., Yu, L., Zhang, Y., Zhang, J., Chen, Y., Hu, J., …, & Zhu, W. (2025). High‐risk screening for late‐onset Pompe disease in China: An expanded multicenter study. Journal of Inherited Metabolic Disease, 48(1). https://doi.org/10.1002/jimd.12793

Vancouver

Jiao K, Zhu B, Chang X, Guo J, Fu J, Song X, et al. High‐risk screening for late‐onset Pompe disease in China: An expanded multicenter study. Journal of Inherited Metabolic Disease. 2025;48(1). doi:10.1002/jimd.12793

BibTeX
@article{Jiao2025,
  author = {Jiao, Kexin and Zhu, Bochen and Chang, Xueli and Guo, Junhong and Fu, Jun and Song, Xueqin and Yu, Xuen and Zhang, Xiaoge and Dong, Jihong and Yan, Wang and Luan, Xinghua and Wang, Zhiqiang and Han, Hong and Du, Lijun and Yu, Liqiang and Zhang, Yali and Zhang, Jingjing and Chen, Yan and Hu, Jing and Zhao, Zhe and Kang, Juan and Tan, Song and Wang, Zhiyun and Mao, Shanshan and Qian, Fangyuan and Luo, Ronghua and Liu, Changxia and Huang, Zhengyu and Li, Gang and Li, Xia and Luo, Lijun and Li, Dong and Zhou, Yuanlin and Hu, Xiafei and Yu, Xuefan and Shi, Yongguang and Jiang, Jianming and Zhang, Jialong and Cheng, Nachuan and Wang, Ningning and Xia, Xingyu and Yue, Dongyue and Gao, Mingshi and Xi, Jianying and Luo, Sushan and Lu, Jiahong and Zhao, Chongbo and Ke, Qing and Ma, Mingming and Zhu, Wenhua},
  title = {High‐risk screening for late‐onset Pompe disease in China: An expanded multicenter study},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {1},
  doi = {10.1002/jimd.12793}
}
Kostenlos starten →